A retrospective cohort study of treatment patterns among patients with metastatic soft tissue sarcoma in the US

ConclusionChoice of regimen by LOT among patients with mSTS is varied;  <  65% of patients in any LOT received the five most common regimens. Pazopanib, the only approved targeted therapy, is primarily used in second and later lines of therapy and is mostly given post docetaxel + gemcitabine.
Source: Clinical Sarcoma Research - Category: Cancer & Oncology Source Type: research